Conventional MRI and Dynamic Contrast-Enhanced MRI in Differentiating Histopathological Subtypes of Giant Cell Tumor of Bone
Keywords:
Giant cell tumor of bone, conventional MRI, dynamic contrast-enhanced MRI, musculoskeletal tumorsAbstract
Background and Aim: Giant cell tumor of bone (GCTB) is a locally aggressive neoplasm with heterogeneous biological behavior, including conventional and malignant subtypes.Accurate preoperative differentiation remains clinically important yet challenging.Although histopathology remains the gold standard for diagnosis, it is invasive and limited in assessing tumor heterogeneity.Conventional MRI is widely used but has limited ability to distinguish histopathological subtypes due to overlapping imaging features. Dynamic contrast-enhanced MRI (DCE-MRI), which reflects tumor perfusion and vascular permeability, may provide additional discriminatory information; however, comparative evidence with conventional MRI remains limited.This study aims to compare conventional MRI and DCE-MRI in differentiating histopathological subtypes of GCTB.
Methods: This retrospective cross-sectional study included 31 patients with histopathologically confirmed GCTB who underwent conventional MRI and DCE-MRI between January 2020 and February 2026.Conventional MRI parameters included tumor volume, solid component volume ratio, and septal thickness. DCE-MRI analysis comprised qualitative (time–intensity curve [TIC] patterns), semi-quantitative (maximum slope and IAUGC), and quantitative parameters (Ktrans, Kep, and Ve). Imaging findings were compared between conventional and malignant subtypes.
Results: Most cases were conventional GCTB (87.1%), with a slight male predominance (54.8%) and the majority aged 20–40 years (58.1%). Lesions were most frequently located in the lower extremities (61.3%), particularly the tibia and femur. Conventional MRI parameters showed no significant differences between histopathological subtypes (p>0.05). Among DCE-MRI parameters, TIC patterns were not significantly different (p=0.340), although all malignant cases demonstrated a type IV pattern. In contrast, quantitative and semi-quantitative DCE-MRI parameters showed significant differences, with higher median values of Ktrans (p=0.009), Kep (p=0.002), IAUGC (p=0.012), and maximum slope (p=0.023) in malignant GCTB, while Ve showed no significant difference (p=0.396).
Conclusions: Conventional MRI has limited ability to differentiate histopathological subtypes of GCTB.In contrast, DCE-MRI parameters provide significant discriminatory information between conventional and malignant subtypes, supporting its role as a non-invasive tool for tumor characterization.
References
1. Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR. Giant Cell Tumor of Bone: Review, Mimics, and New Developments in Treatment. RadioGraphics 2013;33:197–211
2. Parmeggiani A, Miceli M, Errani C, Facchini G. State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics. Cancers 2021;13:6298
3. Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT, Kransdorf MJ. Imaging of Giant Cell Tumor and Giant Cell Reparative Granuloma of Bone: Radiologic-Pathologic Correlation. RadioGraphics 2001;21:1283–1309
4. Gupta A, Nath R, Mishra M. Giant cell tumor of bone: Multimodal approach. Indian J Orthop 2007;41:115
5. Hosseinzadeh S, Tiwari V, De Jesus O. Giant Cell Tumor (Osteoclastoma). In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2026.
6. Chhabra A, Soldatos T. Soft-Tissue Lesions: When Can We Exclude Sarcoma? American Journal of Roentgenology 2012;199:1345–1357
7. Chen L, Shi X, Zhou Z, Qin L, Liu X, Jiang L, et al. Clinical Significance of MRI and Pathological Features of Giant Cell Tumor of Bone Boundary. Orthopaedic Surgery 2019;11:628–634
8. Sharma G, Saran S, Saxena S, Goyal T. Multiparametric evaluation of bone tumors utilising diffusion weighted imaging and dynamic contrast enhanced magnetic resonance imaging. Journal of Clinical Orthopaedics and Trauma 2022;30:101899
9. Zhang Y, Yue B, Zhao X, Chen H, Sun L, Zhang X, et al. Benign or Malignant Characterization of Soft-Tissue Tumors by Using Semiquantitative and Quantitative Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Can Assoc Radiol J 2020;71:92–99
10. Lin F, Hu Y, Zhao L, Zhang H, Yu X, Wang Z, et al. The epidemiological and clinical features of primary giant cell tumor around the knee: A report from the multicenter retrospective study in china. Journal of Bone Oncology 2016;5:38–42
11. Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT-J 2017;3:54
12. Konishi E, Outani H, Mano M, Nagata S, Shirai T, Naka N, et al. Giant cell tumor of bone – Analysis of 213 cases involving extra‐craniofacial bones. Pathology International 2021;71:500–511
13. Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant Cell Tumor of Bone - An Overview. Arch Bone Jt Surg 2016;4:2–9
14. Jha Y, Chaudhary K. Giant Cell Tumour of Bone: A Comprehensive Review of Pathogenesis, Diagnosis, and Treatment. Cureus 2023
15. Jamshidi K, Karimi A, Mirzaei A. Epidemiologic Characteristics, Clinical Behavior, and Outcome of the Giant Cell Tumor of the Bone: A Retrospective Single-center Study. Arch Bone Jt Surg 2019;7:538–544
16. Vari S, Riva F, Onesti CE, Cosimati A, Renna D, Biagini R, et al. Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre. IJMS 2022;23:10721
17. Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in Giant Cell Tumor of Bone: A Review of the Literature. Technol Cancer Res Treat 2019;18:1533033819840000
18. Oh E, Yoon YC, Kim JH, Kim K. Multiparametric approach with diffusion-weighted imaging and dynamic contrast-enhanced MRI: a comparison study for differentiating between benign and malignant bone lesions in adults. Clinical Radiology 2017;72:552–559
19. Lin M, Chen X, Peng Y, Yang C, Wang R. Diagnostic value of IVIM and DCE-MRI parameters for differentiating benign from malignant bone tumors and their correlations with Ki-67 expression. BMC Cancer 2026;26:195
20. Martadiani ED, Sumadi IWJ, Putra IWGAE, Anggreni FN, Martono B, Primanda Y, et al. Diagnostic value of qualitative, semiquantitative, and quantitative parameter of Dynamic Contrast Enhanced MRI in musculoskeletal tumor. Bali Medical Journal 2022;11:2075–2084
21. Libicher M, Bernd L, Schenk JP, Mädler U, Grenacher L, Kauffmann GW. Charakteristisches Perfusionsmuster des ossären Riesenzelltumors in der dynamischen kontrastverstärkten MRT. Der Radiologe 2001;41:577–582
22. Chen L, Ding X-Y, Wang C-S, Si M-J, Du L-J, Lu Y. Triple-phase dynamic MRI: a new clue to predict malignant transformation of giant cell tumor of bone. Eur J Radiol 2014;83:354–359
23. Sollmann N, Fuderer M, Crameri F, Weingärtner S, Baeßler B, Gulani V, et al. Color Maps: Facilitating the Clinical Impact of Quantitative MRI. Magnetic Resonance Imaging 2025;61:1572–1579
24. Yuan J, Chow SKK, Yeung DKW, King AD. A five-colour colour-coded mapping method for DCE-MRI analysis of head and neck tumours. Clinical Radiology 2012;67:216–223
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
